RxDoctor Payments Data

Maria Birotte Sanchez, MD

Family Medicine · North Plainfield, NJNPI 1841326162

Payments from drug & device makers

$4,917in general payments, 2019–2025

Across 299 payments — averaging $16.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$989
  • Lilly USA, LLC$753
  • AstraZeneca$656
  • Bayer$557
  • Amgen$504
  • Sanofi-aventis U.S. LLC$358
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$4,87599%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,917 in reported general payments places this provider in the 85th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$29,785
Medicare patients
52
Services billed
462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide105$103,807
OzempicSemaglutide90$91,116
JardianceEmpagliflozin59$74,508
MounjaroTirzepatide59$62,341
JanuviaSitagliptin Phosphate43$56,949
RybelsusSemaglutide24$48,510
ProliaDenosumab25$42,234
FarxigaDapagliflozin Propanediol45$41,050
KerendiaFinerenone28$34,231
Bydureon BciseExenatide Microspheres24$19,546
LinzessLinaclotide24$18,592
EliquisApixaban25$18,504
VascepaIcosapent Ethyl38$17,776
Janumet XrSitagliptin Phos/Metformin Hcl15$13,429
MyrbetriqMirabegron13$11,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$753$166,147164 claims
Novo NordiskOzempic, Rybelsus$989$139,626114 claims
Boehringer IngelheimJardiance$107$74,50859 claims
MerckJanuvia, Janumet Xr$78$70,37958 claims
AstraZenecaFarxiga, Breztri Aerosphere$656$48,72457 claims
AmgenProlia$504$42,23425 claims
BayerKerendia$557$34,23128 claims
AbbVieLinzess$81$18,59224 claims
PfizerEliquis$63$18,50425 claims
GSKTrelegy Ellipta$103$11,62116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in North Plainfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →